Proto-Oncogene Proteins c-met
-
Subject Areas on Research
-
A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial.
-
A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets.
-
Aberrant activation of hepatocyte growth factor/MET signaling promotes β-catenin-mediated prostatic tumorigenesis.
-
Abl Kinases Regulate HGF/Met Signaling Required for Epithelial Cell Scattering, Tubulogenesis and Motility.
-
Activating mutation in MET oncogene in familial colorectal cancer.
-
Acute tissue injury activates satellite cells and promotes sarcoma formation via the HGF/c-MET signaling pathway.
-
Adaptation and selection shape clonal evolution of tumors during residual disease and recurrence.
-
An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.
-
Chromosomal amplification of leucine-rich repeat kinase-2 (LRRK2) is required for oncogenic MET signaling in papillary renal and thyroid carcinomas.
-
Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET.
-
Crizotinib and erlotinib inhibits growth of c-Met+/EGFRvIII+ primary human glioblastoma xenografts.
-
Cyr61 mediates hepatocyte growth factor-dependent tumor cell growth, migration, and Akt activation.
-
Decreased fibronectin expression in Met/HGF-mediated tumorigenesis.
-
Degradation of the Met tyrosine kinase receptor by the ubiquitin-proteasome pathway.
-
Development of a Novel c-MET-Based CTC Detection Platform.
-
Differential expression of receptor tyrosine kinases (RTKs) and IGF-I pathway activation in human uterine leiomyomas.
-
EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts.
-
Evaluation of the pharmacokinetic drug interaction potential of tivantinib (ARQ 197) using cocktail probes in patients with advanced solid tumours.
-
Evidence for a role of Met-HGF/SF during Ras-mediated tumorigenesis/metastasis.
-
First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.
-
Genomic Status of MET Potentiates Sensitivity to MET and MEK Inhibition in NF1-Related Malignant Peripheral Nerve Sheath Tumors.
-
Hepatocyte growth factor and myopia: genetic association analyses in a Caucasian population.
-
Hepatocyte growth factor enhances death receptor-induced apoptosis by up-regulating DR5.
-
Improving the clinical risk score: an analysis of molecular biomarkers in the era of modern chemotherapy for resectable hepatic colorectal cancer metastases.
-
Inhibition of c-Met as a therapeutic strategy for esophageal adenocarcinoma.
-
Inhibition of rhabdomyosarcoma cell and tumor growth by targeting specificity protein (Sp) transcription factors.
-
MET and phosphorylated MET as potential biomarkers in lung cancer.
-
Met and hepatocyte growth factor/scatter factor expression in human gliomas.
-
Mutations Preventing Regulated Exon Skipping in MET Cause Osteofibrous Dysplasia.
-
Novel role for endogenous hepatocyte growth factor in the pathogenesis of intracranial aneurysms.
-
PTEN reconstitution alters glioma responses to c-Met pathway inhibition.
-
Pathogenic Germline Variants in 10,389 Adult Cancers.
-
Personalized treatment of lung cancer.
-
Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti-c-Met Antibody, in Patients with Advanced Solid Tumors.
-
Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma.
-
Profiling the dynamics of a human phosphorylome reveals new components in HGF/c-Met signaling.
-
Role of cyclin D1 as a mediator of c-Met- and beta-catenin-induced hepatocarcinogenesis.
-
SPSB1 promotes breast cancer recurrence by potentiating c-MET signaling.
-
Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer.
-
Systemic Therapy for Non-Clear Cell Renal Cell Carcinoma.
-
Targeted therapy for infants with diencephalic syndrome: A case report and review of management strategies.
-
Targeting MET Amplification with Crizotinib in a Case of Sinonasal Undifferentiated Carcinoma.
-
The role of cytoprotective cytokines in cardiac ischemia/reperfusion injury.
-
Three-genome mosses: complex double allopolyploid origins for triploid gametophytes in Sphagnum.
-
c-MET and HGF mRNA expression in hepatocellular carcinoma: correlation with clinicopathological features and survival.
-
Keywords of People